ARCHIVES

Translplants Not Best Choice in Subset of ALL Patients

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

July 27, 2012

NTP Establishes Panel To Write New Guidelines For Detection, Evaluation Of Chemical Carcinogens

April 1, 1983

Amgen Takes Its Case for Aranesp To Lawmakers, Patients, Physicians

January 31, 2003

Cell Culture ID Offered By NIC

January 7, 1983

ASCO Draft Recommendations Define Meaningful Trial Outcomes

April 26, 2013

NIH Acting Director Kirschstein Preparing For Budget Hearings.

January 14, 2000